BMS, AbbVie land Breakthrough label

Bristol-Myers Squibb and AbbVie pocketed a Breakthrough Therapy designation for the experimental multiple myeloma medication elotuzumab.

The companies announced the expedited FDA review classification of their monoclonal antibody Monday. The experimental drug is being investigated for use in tandem with lenalidomide and dexamethasone for patients who have already received at least one or two rounds of prior therapy.

The companies said the FDA handed over the label based on open-label Phase-II data.

BMS and AbbVie are co-developing the drug, and BMS is taking the lead on its commercialization.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.